In context
Des(1–3) IGF-I is a shortened insulin-like growth factor variant. A laboratory experiment compared its effects with related growth factors in isolated rat pancreatic islets. [1]
At a glance
- Type
- Peptide / related experimental research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- An isolated-islet experiment examines secretion mechanisms. It cannot establish human muscle growth, treatment safety or equivalence to a licensed IGF-I medicine.
How to interpret this evidence
An isolated-islet experiment examines secretion mechanisms. It cannot establish human muscle growth, treatment safety or equivalence to a licensed IGF-I medicine. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.